Cantor Fitzgerald reissued their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report report published on Tuesday morning. The brokerage currently has a $140.00 target price on the biotechnology company’s stock.
“. $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study.”,” Cantor Fitzgerald’s analyst wrote.
Other analysts have also recently issued reports about the company. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the company a buy rating in a research report on Thursday, September 27th. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the company a buy rating in a research report on Friday, September 14th. JMP Securities decreased their target price on AnaptysBio from $180.00 to $153.00 and set a buy rating for the company in a research report on Wednesday, August 15th. Jefferies Financial Group reissued a buy rating and issued a $121.00 target price on shares of AnaptysBio in a research report on Tuesday, August 7th. Finally, Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $93.00 target price for the company in a research report on Monday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $130.90.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. On average, sell-side analysts anticipate that AnaptysBio will post -2.72 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of ANAB. Wells Fargo & Company MN lifted its position in AnaptysBio by 53.8% during the 1st quarter. Wells Fargo & Company MN now owns 36,294 shares of the biotechnology company’s stock worth $3,777,000 after acquiring an additional 12,701 shares during the period. Northern Trust Corp lifted its position in AnaptysBio by 4.3% during the 1st quarter. Northern Trust Corp now owns 197,970 shares of the biotechnology company’s stock worth $20,605,000 after acquiring an additional 8,164 shares during the period. BlackRock Inc. lifted its position in AnaptysBio by 2.1% during the 1st quarter. BlackRock Inc. now owns 1,423,117 shares of the biotechnology company’s stock worth $148,119,000 after acquiring an additional 29,812 shares during the period. New York State Common Retirement Fund lifted its position in AnaptysBio by 56.2% during the 1st quarter. New York State Common Retirement Fund now owns 21,839 shares of the biotechnology company’s stock worth $2,273,000 after acquiring an additional 7,855 shares during the period. Finally, California Public Employees Retirement System acquired a new stake in AnaptysBio during the 1st quarter worth approximately $2,520,000.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Recommended Story: Fundamental Analysis
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.